• Profile
Close

Ritlecitinib and brepocitinib phase 2a randomized trial results review for alopecia areata treatment

Journal of the European Academy of Dermatology and Venereology Jan 28, 2022

NOTE, original article title: Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib

In the ALLEGRO trial, adults with alopecia areata were randomized to ritlecitinib (n = 48), brepocitinib (n = 47) or placebo (n = 47), and this analysis was conducted to report scores from the Alopecia Areata Symptom Impact Scale (AASIS; a patient-reported outcome tool) as well as to examine the associations of those scores with clinician-evaluated Severity of Alopecia Tool (SALT) scores at baseline and week 24 of the ALLEGRO trial.

  • Treatment groups had similar baseline AASIS and SALT scores.

  • At week 24, significantly improved AASIS and SALT scores were seen in patients randomized to ritlecitinib or brepocitinib, vs placebo.

  • Improvements in the mean SALT scores (standard deviation) relative to baseline were evident at week 24 [ritlecitinib, 54.4 (40.3) vs 89.4 (15.8); brepocitinib, 31.9 (35.7) vs 86.4 (18.1)].

  • At week 24, medium-to-large correlations can be observed between AASIS global and subscale scores and SALT scores.

  • Overall, new patient-reported outcome tools are required to correctly evaluate patients' relevant alopecia areata associated signs, symptoms and daily functioning.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay